Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Items 501–588 of 588
Morgado‐Carrasco, D., Fustà‐Novell, X., Riera‐Monroig, J., & Iranzo, P. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2018.04.006
“21% for placebo), although it did not reduce the body surface area affected.(4) Another promising drug is topical tofacitinib 2%, which inhibits janus kinases 1 and 3 and the activity of IL-2, IL-4, and other proinflammatory cytokines.”
BackgroundDermatitis atópica del adulto: de la fisiopatología a la terapéutica (II)
Rodríguez, J., Alcantara‐Luna, S., Hita, J. C. A., & Martínez-Pilar, L. (2018) · Piel · doi:10.1016/j.piel.2018.01.015
Actualización en el tratamiento de la dermatitis atópica
Valenzuela, F., & Yumha-Laiz, J. (2018) · Piel · doi:10.1016/j.piel.2018.07.020
Pathophysiology and new treatment of itch
Jung, M. J., Choi, Y. W., Chung, B. Y., Park, C. W., & Kim, H. O. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.11.670
Zahlreiche Biologika in der Pipeline
Werfel, T. (2019) · hautnah dermatologie · doi:10.1007/s15012-019-3006-8
Prurigo pós radioterapia: estudo clínico, histológico e imunohistoquímico
Francesconi, F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-13022019-151657
Thérapeutiques ciblées dans les maladies inflammatoires cutanées
Bachelez, H. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30160-8
Evaluation and Management of the Patient with Pruritus
Tamargo, K., Funovits, A., Nguyen, T. H., Manudhane, A. P., & Montanez-Wiscovich, M. E. (2019) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-019-00137-7
Therapie der atopischen Dermatitis
Werfel, T. (2019) · hautnah · doi:10.1007/s12326-019-00346-w
Prurido crónico – Da etiologia ao tratamento
Valente, C., & Rosmaninho, I. (2019) · Revista Portuguesa de Imunoalergologia · doi:10.32932/rpia.2019.07.017
Traidl, S., Werfel, T., & Heratizadeh, A. (2019) · Der Deutsche Dermatologe · doi:10.1007/s15011-019-2485-6 · Cited by 1
1) Anti-cytokine Therapies for Atopic Dermatitis and Psoriasis - from the View of a Dermatologist
Kabashima, K., & Egawa, G. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.381
Self-citationPediatric allergic diseases and molecular targeting drugs
Okafuji, I. (2020) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.34.243
New Treatments for Atopic Dermatitis
Yoshihara, N., & Ikeda, S. (2020) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.2020.66.jmj20-r04
20-Year-Old Female with Diffuse Itchy, Scaly Skin
Haught, E., Cusick, A. S., & Trotter, S. C. (2021) · Clinical Cases in Dermatology · doi:10.1007/978-3-030-66274-5_3
27-Year-Old Pregnant Female with a Pruritic Eruption on the Trunk and Extremities
Bushrow, L., Cusick, A. S., & Trotter, S. C. (2021) · Clinical Cases in Dermatology · doi:10.1007/978-3-030-66274-5_24
26-Year-Old Female with Itchy, Blisters on the Bilateral Arms and Buttocks
Baah, N., Cusick, A. S., & Trotter, S. C. (2021) · Clinical Cases in Dermatology · doi:10.1007/978-3-030-66274-5_12
Atopic dermatitis – Recent advances in the management
Ramamoorthy, R. (2021) · Journal of Skin and Sexually Transmitted Diseases · doi:10.25259/jsstd_10_2021
Lima, L. D. P. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-28092021-090259 · Cited by 1
Alle soglie dell’anima: Vitaliano Brancati e l’avventura dell’inconscio
Giannetti, V. (2011) · HAL
Integral: tercer curso [B.U.P.]: matemáticas
Agustí, J. M., & Vila, A. (1977) · Dialnet (Universidad de la Rioja)
Research-and-teaching elective in a primary care oriented school.
Pantoja, E., Zambernard, J., Nagy, F., Ream, L., & Rj, M. (1984) · PubMed
Prurigo nodularis, prurigo chronica, new therapeutic options
Bata‐Csörgõ, Z. (2021) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2021.97.5.6
Kirchner, A., & Lake, E. P. (2022) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000661
Saeki, H., & Ichiyama, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736478775.793566886
The new and old: Atopic dermatitis biologics
Logas, C. M., Glick, B. P., & Rosso, J. Q. D. (2022) · Dermatological Reviews · doi:10.1002/der2.105
“pruritus, improved sleep quality, increased in the Dermatology Life Quality Index, and dose dependent reductions in EASI scores.(32)”
BackgroundSkin-Gut-Lung Epithelial Permeability
Kost, Y., Zhu, T. H., Zhu, T. R., & Shi, V. Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-84744-5.00015-2
Moderne Systemtherapeutika revolutionieren die Behandlung
Kirsten, N. (2022) · Der Deutsche Dermatologe · doi:10.1007/s15011-022-4903-4
Morán‐Villaseñor, E., & García‐Romero, M. T. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815039658122010012
山出史也 (2018) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.32.301
Homey, B., Ruzicka, T., & Wollenberg, A. (2017) · Springer eBooks · doi:10.1007/978-3-662-49546-9_32-2
Self-citationCurrent approaches to the treatment of atopic dermatitis: a review of the literature
Bakurov, E. V. (2021) · Russian Journal of Skin and Venereal Diseases · doi:10.17816/dv81397 · Cited by 1
Neue Substanz erfolgreich getestet
Heidelberg, S.-V. B. (2017) · ästhetische dermatologie & kosmetologie · doi:10.1007/s12634-017-5422-2
Chinese Guidelines for the Management of Chronic Pruritus (2018)
The Allergic Disease Committee of Chinese Dermatologist Association (2020) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000073
2) Pathogenesis and Novel Therapeutic Strategies in Atopic Dermatitis
Kabashima, K. (2020) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.109.1741
Self-citationKim, H. O. (2021) · Springer eBooks · doi:10.1007/978-981-15-8159-5_4
Clinical observations of complex therapy of atopic dermatitis of moderate severity
Stadnikova, A. S. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-12-100-104
Itch and the Antipruritic Effect of Acupuncture
Mi, W., Du, L., & Yang, Y. (2022) · Springer eBooks · doi:10.1007/978-3-030-96221-0_18
Cytokines, Interferons, and Hematopoietic Growth Factors
Epperla, N., Hanel, W. G., & Talpaz, M. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm064.pub2
Management of Moderate-to-Severe Atopic Dermatitis in the Era of Targeted Treatments
Coates, S. (2019) · European Medical Journal · doi:10.33590/emj/10312260
Rôle de l’interleukine 31, une cytokine neuro-immune, dans le prurit et au-delà
Misery, L. (2023) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/j.fander.2022.12.005
Weber, M. B., Camozzato, F. O., & Recuero, J. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-13505-7_67 · Cited by 2
Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis
Atluri, K., Manne, S., Nalamothu, V., Mantel, A., Sharma, P. K., & Babu, R. J. (2023) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2023042979
Atopic Dermatitis in the Adult Population
Baumann, J. R., Groneck, A., & Martin, K. L. (2023) · Archives of Family Medicine and General Practice · doi:10.36959/577/508
Dermatitis atópica del adulto: un desafío diagnóstico y terapéutico
Daniela Carvajal, A., Fernando Valenzuela, A., Javier Fernández, M., & Andrea Zamudio, M. (2019) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2019.70240 · Cited by 4
Special Therapeutic Options and Substances in the Treatment of Atopic Eczema
Eyerich, K., & Ring, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-12499-0_7 · Cited by 2
Biologics in the Management of Sever Atopic Dermatitis
Abadie, M. A., Sharara, Z., & Al Abadie, S. (2023) · International Journal of Clinical & Experimental Dermatology · doi:10.33140/ijced.08.02.05
Skayem, C., & Duong, T. A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004103 · Cited by 1
Ardern‐Jones, M. R., Flohr, C., & Reynolds, N. J. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook041
CytoSIP: an annotated structural atlas for interactions involving cytokine or cytokine receptor
Wang, L., Sun, F. Z., Ma, H., Zhong, J., Zhang, H., Cheng, S., Wu, H., Wang, N., Zhao, M., Zhu, P., et al. (2023) · Acta Crystallographica Section A Foundations and Advances · doi:10.1107/s2053273323082396
Prurit et douleur cutanée au cours de la dermatite atopique
Misery, L. (2024) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(24)00190-9
Targeted Therapy for Atopic Dermatitis: A Novel Approach
Chauhan, M., Mazumder, R., Rani, A., Kumar, A., & Chaitanya, M. (2024) · Current Drug Therapy · doi:10.2174/0115748855307501240607045747
ATOPİK DERMATİT TEDAVİSİNDE BİYOLOJİK İLAÇLAR: LİTERATÜR TARAMASI
Çalıcıoğlu, F., Çalıcıoğlu, N., Avcı, A., Ulaş, Y., & Ertaş, R. (2024) · Journal of Anatolian Medical Research · doi:10.55694/jamer.1410278 · Cited by 1
Mechanisms and Therapeutic Targets of Staphylococcus Aureus - Induced Itch in Atopic Dermatitis
Lagaros, T., Broshtilova, V., Yungareva, I., Velevska, Y., Trenovski, A., & Márina, S. S. (2024) · International Journal of Clinical Dermatology · doi:10.11648/j.ijcd.20240702.11
Dermatologische Erkrankungsbilder
Siebdrath, J., Winkler, D., & Welzel, J. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21442-4.00022-x
Yamamoto, T. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17538 · Cited by 2
Yong, J. F., Lai, F. Y., Hackett, C. B., & Tobin, A. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf042
Song, J., Yang, J., Yan, Y., Liu, T., Fan, J., & Jiao, H. (2025) · Aesthetic Plastic Surgery · doi:10.1007/s00266-025-04692-4
Ibrahim, R. S. A. R., Ismail, N. A., Abdallah, M. O., & Atwa, M. A. (2025) · Egyptian Journal of Dermatology and Venerology · doi:10.4103/ejdv.ejdv_50_24
Finding Nemolizumab a Role in a Rising Sea of Treatment Options for Atopic Dermatitis
Patel, N. P., Hussain, K., & George, C. (2025) · International Journal of Dermatology · doi:10.1111/ijd.70058
Singto, T., Filor, V., Vidak, J., Klopfleisch, R., & Bäumer, W. (2024) · Figshare · doi:10.6084/m9.figshare.25210670
Dias-Barbosa, C., Silverberg, J. I., Ständer, S., Rodriguez, D., Fofana, F., Filipenko, D., Ulianov, L., Piketty, C., & Puelles, J. (2024) · Figshare · doi:10.6084/m9.figshare.26749454
Dias-Barbosa, C., Silverberg, J. I., Ständer, S., Rodriguez, D. N., Fofana, F., Filipenko, D., Ulianov, L., Piketty, C., & Puelles, J. (2024) · Figshare · doi:10.6084/m9.figshare.26749451
Singto, T., Filor, V., Vidak, J., Klopfleisch, R., & Bäumer, W. (2024) · Figshare · doi:10.6084/m9.figshare.25210851
Dias-Barbosa, C., Silverberg, J. I., Ständer, S., Rodriguez, D., Fofana, F., Filipenko, D., Ulianov, L., Piketty, C., & Puelles, J. (2024) · Figshare · doi:10.6084/m9.figshare.26749457
Assessment of IL-13, IL-31 Levels and Disease Severity in Children with Atopic Dermatitis
Missaoui, S., Abbari, I., Kholaiq, H., Aadam, Z., Oussama, K., Errami, A., Ailal, F., Benhsaien, I., Baghad, B., Bakkouri, J. E., et al. (2025) · Dermato · doi:10.3390/dermato6010001
“Likewise, the phase II trial by Ruzicka [20] showed that nemolizumab, an anti-IL-31RA antibody, induced a rapid and significant reduction in pruritus without proportional improvement in skin lesions.”
Zhang, L., Gong, Y., Gu, X., Liu, Y., Chen, M., Yi, Q., Jia, J., Li, L., Xu, L., & Zheng, Q. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03957-w
Enigmatic Role of IL-31 in the Itch and Inflammation of Vernal Keratoconjunctivitis
Okamoto, M., Tominaga, M., Mashimo, K., Usui‐Ouchi, A., & Ebihara, N. (2026) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj25-0022-oa
Kim, T.-H., Shin, S., & Park, W. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00809-2
Reconstitution in vitro des réponses immunitaires initiales dans la dermatite atopique
Brulefert, A. (2020) · theses.fr (ABES) · doi:10.70675/4f0faf3cz1452z496dz8fe2z3a669eab038a
Lefèvre‐Utile, A. (2021) · theses.fr (ABES) · doi:10.70675/e862df74z545az4e0bza70az48ee9411c538
Takeuchi, F., Yoneshige, A., Shoya, Y., Hagiyama, M., Inoué, T., & Ito, A. (2026) · Medical Principles and Practice · doi:10.1159/000552015
Litewczuk, D., Truini, A., Schmelz, M., & Rukwied, R. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.05.004
Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety
Masoumi, N., Monadi, T., Aminzade, Z., Soltani, A., Noqani, H., & Enderami, S. E. (2026) · Current Therapeutic Research · doi:10.1016/j.curtheres.2026.100833
Wollenberg, A., Silverberg, J. I., Legat, F. J., Tauber, M., Laquer, V. T., Armstrong, A. W., Pink, A., Naldi, L., Pulka, G., Zdybski, J., et al. (2026) · Acta Dermato Venereologica · doi:10.2340/actadv.v106.adv-2025-0085 · Cited by 2
Self-citationAdam, D. N., Dhadwal, G., Grewal, P. S., Ringuet, J., Turchin, I., & Beecker, J. R. (2026) · Dermatologic Therapy · doi:10.1155/dth/6874662
Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria
Salavoura, A. (2026) · Dermatology Research and Practice · doi:10.1155/drp/5283760
Soenoe, M. S., & Hadi, S. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04760-y
Shen, Y., Shen, Q., Chen, M., & Liu, R. (2026) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.71111
Miyamoto, T., Ohira, C., Kaneki, M., Komuro, M., Ichikawa, M., Yasuda, I., Takagi, Y., & Fukuyama, T. (2026) · Brain and Behavior · doi:10.1002/brb3.71731
Toader, M. P., Hrițcu, O. M. C., Grigorovici, M., Toader, S. V., Solcan, C., & Branisteanu, D. E. (2026) · Diagnostics · doi:10.3390/diagnostics16183047
Mansour, E., Karam, F., Nahas, K. A., Abboud, R.-M., Rizk, N., Douaihy, D. E., Ammouri, H. A., Ghadieh, H. E., Khattar, Z. A., Azar, S. T., et al. (2026) · Sage Open Chronic Disease · doi:10.1177/27558428261488943
IL-31 targets the hair follicle bulge across species and delays plucking-induced anagen in mice
Katsuo, K., Nakamizo, S., Egawa, G., Kitoh, A., Nakajima, S., Okada, T., & Kabashima, K. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.10.005
Self-citationTeng, Y., Pu, T., Wang, F., & Da, M. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09213-y
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.